Phase I trial of MDXH210 (FeγRI×HER-2/neu, bispecific antibody) in combination with G-CSF in patients with metastatic breast cancer: H. van Ojik1, G. Groenewegen1, R. Repp3, T. Valerius3, A. van Oers2, N.A.C. Westerdaal2, Y. Deo4, G.H. Blijham1, J.G.J. van de Winkel2. Departments of Internal Medicine1 and Immunology2, University Hospital, Utrecht, Netherlands, Department of Medicine III, University of Erlangen-Nurnberg3, with Germany, support from Medarex4, Annandale, NJ, USA